<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35037787</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-092X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</Title>
          <ISOAbbreviation>J Oncol Pharm Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lichen planopilaris-like eruption in chronic myeloid leukemia patient during treatment with nilotinib as second-line therapy.</ArticleTitle>
        <Pagination>
          <StartPage>969</StartPage>
          <EndPage>971</EndPage>
          <MedlinePgn>969-971</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/10781552211073957</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Chronic myeloid leukemia (CML) is a malignant clonal disorder of hematopoietic stem cells characterized by a translocation of genetic material between chromosomes 9 and 22 resulting in the BCR-ABL fusion oncogene expression. Nilotinib is a potent second-generation tyrosine kinase inhibitor available as first line treatment. Among side effects QTc interval prolongation, pancreatitis, metabolic disorders and skin reactions are the most commonly seen.</AbstractText>
          <AbstractText Label="CASE REPORT" NlmCategory="METHODS">Here we describe a rare case of lichen planopilaris eruption that developed during therapy with nilotinib.</AbstractText>
          <AbstractText Label="MANAGEMENT &amp; OUTCOME" NlmCategory="METHODS">Nilotinib dosage was reduced together with introduction of hydroxychloroquine with progressive improvement of alopecia.</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Collaboration with dermatologist and nilotinib dose reduction allowed to continue the drug maintaining major molecular response and patient's quality of life.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gardellini</LastName>
            <ForeName>Angelo</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Department of Medicine, 9349Valduce Hospital, Como, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guidotti</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0002-9030-1557</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Department of Medicine, 9349Valduce Hospital, Como, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zancanella</LastName>
            <ForeName>Michelle</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Department of Medicine, 9349Valduce Hospital, Como, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maino</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Department of Medicine, 9349Valduce Hospital, Como, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steffanoni</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Department of Medicine, 9349Valduce Hospital, Como, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turrini</LastName>
            <ForeName>Mauro</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Department of Medicine, 9349Valduce Hospital, Como, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Oncol Pharm Pract</MedlineTA>
        <NlmUniqueID>9511372</NlmUniqueID>
        <ISSNLinking>1078-1552</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D016044">Fusion Proteins, bcr-abl</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>F41401512X</RegistryNumber>
          <NameOfSubstance UI="C498826">nilotinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C535892">Lichen planus follicularis</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005076" MajorTopicYN="Y">Exanthema</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016044" MajorTopicYN="N">Fusion Proteins, bcr-abl</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015464" MajorTopicYN="Y">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008010" MajorTopicYN="Y">Lichen Planus</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>12</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35037787</ArticleId>
        <ArticleId IdType="doi">10.1177/10781552211073957</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
